Early identification of congenital hypothyroid infants with abnormalities in pituitary setpoint for T4-induced TSH...

Area of Science:

• Pediatric Endocrinology
• Neonatal Screening
• Thyroid Disorders

Background:

• Early detection and treatment of congenital hypothyroidism (CH) are crucial for normal growth and psychomotor development.
• Some infants treated for CH may exhibit persistent alterations in the feedback control of thyroid-stimulating hormone (TSH) release by thyroxine (T4).

Purpose of the Study:

• To investigate the phenomenon of persistent alterations in T4 feedback control of TSH release in treated CH children.
• To identify potential markers for detecting these alterations early in infancy.

Main Methods:

• Study included 25 treated CH children, divided into two groups based on the timing of TSH suppression (early vs. late).
• Clinical data, serum T4, T3, and TSH levels were monitored throughout the follow-up period (up to 14 years).
• Thyroxine (LT4) dosage adjustments were made to assess their impact on TSH levels.

Main Results:

• No significant differences were found in CH etiology, mean T4/T3 levels, or LT4 dosage between the groups.
• Children in Group B (late TSH suppression) consistently had elevated serum TSH levels compared to Group A (early TSH suppression).
• Increased LT4 dosage suppressed TSH in both groups, but levels remained higher in Group B, suggesting an abnormal T4 feedback setpoint.

Conclusions:

• Some infants with CH may have an abnormal setpoint for T4 control of TSH secretion, detectable as early as 1 month after birth.
• Serum T4, T3 levels, and clinical progress are more reliable indicators of adequate therapy in these infants than serum TSH concentrations.
• This finding highlights the need for individualized monitoring in CH patients beyond standard TSH levels.